| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.0021 | 0.9 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.003 | 1 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.0019 | 1 |